Advertisement
Advertisement
NVCR
NovoCure Limited Ordinary Shares
10.54
USDSponsored
-0.01
-0.06%
Apr 06, 16:00 UTC -4
Closed
After-Market
10.54
0.00
+0.01%
NVCR Earnings Reports
Positive Surprise Ratio
NVCR beat 24 of 41 last estimates.
59%
Next Report
Date of Next Report
Apr 20, 2026
Estimate for Q1 26 (Revenue/ EPS)
$171.22M
/-$0.52
Implied change from Q4 25 (Revenue/ EPS)
-1.79%
/+136.36%
Implied change from Q1 25 (Revenue/ EPS)
+10.47%
/+67.74%
NovoCure Limited Ordinary Shares earnings per share and revenue
On Feb 26, 2026, NVCR reported earnings of -0.22 USD per share (EPS) for Q4 25, beating the estimate of -0.41 USD, resulting in a 47.58% surprise. Revenue reached 174.35 million, compared to an expected 176.82 million, with a -1.40% difference. The market reacted with a -3.74% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of -0.52 USD, with revenue projected to reach 171.22 million USD, implying an increase of 136.36% EPS, and decrease of -1.79% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Forte Biosciences, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.23
Actual
-$1.39
Surprise
-12.31%
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.44
Actual
-$1.91
Surprise
-32.66%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
Tvardi Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.65
Actual
-$0.78
Surprise
-18.33%
Femasys Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.80%
Tevogen Bio Holdings Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$2.04
Actual
-$1.45
Surprise
+28.92%
Kairos Pharma, Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.07
Surprise
-28.68%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
Soligenix, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.57
Actual
-$0.28
Surprise
+50.98%
FAQ
What were NovoCure Limited Ordinary Shares's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, NovoCure Limited Ordinary Shares reported EPS of -$0.22, beating estimates by 47.58%, and revenue of $174.35M, -1.4% below expectations.
How did the market react to NovoCure Limited Ordinary Shares's Q4 2025 earnings?
The stock price moved down -3.74%, changed from $14.18 before the earnings release to $13.65 the day after.
When is NovoCure Limited Ordinary Shares expected to report next?
The next earning report is scheduled for Apr 20, 2026.
What are the forecasts for NovoCure Limited Ordinary Shares's next earnings report?
Based on 7
analysts, NovoCure Limited Ordinary Shares is expected to report EPS of -$0.52 and revenue of $171.22M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement